$8.28
2.24% day before yesterday
Nasdaq, Dec 27, 10:07 pm CET
ISIN
US6700021040
Symbol
NVAX
Sector
Industry

Novavax, Inc. Stock price

$8.28
-0.34 3.94% 1M
-4.55 35.46% 6M
+3.48 72.50% YTD
+3.34 67.61% 1Y
-149.52 94.75% 3Y
+4.29 107.52% 5Y
-111.32 93.08% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
-0.19 2.24%
ISIN
US6700021040
Symbol
NVAX
Sector
Industry

Key metrics

Market capitalization $1.33b
Enterprise Value $639.56m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 0.72
P/S ratio (TTM) P/S ratio 1.50
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth -15.68%
Revenue (TTM) Revenue $885.19m
EBIT (operating result TTM) EBIT $-289.96m
Free Cash Flow (TTM) Free Cash Flow $-110.85m
Cash position $920.08m
EPS (TTM) EPS $-2.26
P/E forward negative
P/S forward 1.94
EV/Sales forward 0.93
Short interest 30.97%
Show more

Is Novavax, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Novavax, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Novavax, Inc. forecast:

3x Buy
50%
2x Hold
33%
1x Sell
17%

Analyst Opinions

6 Analysts have issued a Novavax, Inc. forecast:

Buy
50%
Hold
33%
Sell
17%

Financial data from Novavax, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
885 885
16% 16%
100%
- Direct Costs 293 293
18% 18%
33%
593 593
14% 14%
67%
- Selling and Administrative Expenses 388 388
11% 11%
44%
- Research and Development Expense 447 447
46% 46%
51%
-243 -243
58% 58%
-27%
- Depreciation and Amortization 47 47
22% 22%
5%
EBIT (Operating Income) EBIT -290 -290
53% 53%
-33%
Net Profit -285 -285
48% 48%
-32%

In millions USD.

Don't miss a Thing! We will send you all news about Novavax, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Novavax, Inc. Stock News

Neutral
PRNewsWire
16 days ago
Novavax continues to progress Sanofi agreement by achieving first milestone, with additional milestones and ongoing tiered royalties to come, solidifying a strong model for future partnerships Novavax's COVID-19 vaccine included in Sanofi's two combination vaccine candidates for prevention of influenza and COVID-19, for which Phase 1/2 trials were initiated and Fast Track designation recently g...
Neutral
PRNewsWire
19 days ago
Company continuing to work with the U.S. FDA on potential for accelerated approval pathway Novavax intends to partner on both candidates to advance to filing and commercialization GAITHERSBURG, Md. , Dec. 10, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that the first participants have been dose...
Positive
The Motley Fool
24 days ago
Many companies that performed well in the early pandemic years have since fallen off the radar or at least have seen their shares drop substantially during the past three years. Telemedicine Teladoc Health (TDOC 0.64%) and vaccine maker Novavax (NVAX -1.31%) belong in this group: Both have significantly lagged behind the market since 2021.
More Novavax, Inc. News

Company Profile

Novavax, Inc. is operates as a clinical-stage biotechnology company, which focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It produces vaccine candidates to respond to both known and emerging disease threats by using the proprietary recombinant nanoparticle vaccine technology. The firm's vaccine candidates include ResVax and NanoFlu. It also develops immune stimulating saponin-based adjuvants through its wholly owned Swedish subsidiary, Novavax AB. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Head office United States
CEO John Jacobs
Employees 1,543
Founded 1987
Website www.novavax.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today